NVAX - Novavax, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Gaithersburg,
United States
Type: Equity
NVAX price evolution
NVAX
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $690.65 | $491.04 | $578.93 | |
| Short term investments | $369.43 | |||
| Net receivables | $94.96 | $32.1 | $21.38 | $297.24 |
| Inventory | $8.64 | $9.17 | $15.78 | $41.7 |
| Total current assets | $1103.68 | $1203.37 | $727.12 | $1143.89 |
| Long term investments | ||||
| Property, plant & equipment | $451.49 | $458.07 | $472.27 | $490.99 |
| Goodwill & intangible assets | $123.38 | $123.18 | $127.45 | |
| Total noncurrent assets | $615.28 | $626.41 | $653.6 | |
| Total investments | $369.43 | |||
| Total assets | $1712.48 | $1818.65 | $1353.53 | $1797.49 |
| Current liabilities | ||||
| Accounts payable | $57.52 | $79.96 | $57.72 | $132.61 |
| Deferred revenue | $1199.82 | $1082.37 | $863.52 | |
| Short long term debt | $9.43 | $6.29 | $5.14 | |
| Total current liabilities | $1181 | $1157.81 | $804.38 | $1635.14 |
| Long term debt | $223.63 | $223.82 | $223.04 | $223.94 |
| Total noncurrent liabilities | $1092.54 | $1416.24 | $879.28 | |
| Total debt | $233.25 | $229.33 | $229.08 | |
| Total liabilities | $2238.92 | $2250.35 | $2220.62 | $2514.42 |
| Shareholders' equity | ||||
| Retained earnings | -$4927.42 | -$4806.12 | -$4968.5 | -$4820.95 |
| Other shareholder equity | $3.6 | -$10.51 | -$10.82 | $2.72 |
| Total shareholder equity | -$431.71 | -$867.08 | -$716.93 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $578.93 | $1347.19 | $1526.61 | $648.74 |
| Short term investments | $157.65 | |||
| Net receivables | $297.24 | $82.38 | $454.99 | $262.01 |
| Inventory | $41.7 | $36.68 | ||
| Total current assets | $1143.89 | $1703.39 | $2155.12 | $1248.2 |
| Long term investments | ||||
| Property, plant & equipment | $490.99 | $400.49 | $228.7 | $179.95 |
| Goodwill & intangible assets | $127.45 | $126.33 | $136.25 | $141.1 |
| Total noncurrent assets | $653.6 | $555.29 | $421.63 | $334.28 |
| Total investments | $157.65 | |||
| Total assets | $1797.49 | $2258.68 | $2576.75 | $1582.48 |
| Current liabilities | ||||
| Accounts payable | $132.61 | $216.52 | $127.05 | $54.33 |
| Deferred revenue | $863.52 | $549.55 | $1595.47 | $273.23 |
| Short long term debt | $5.14 | $352.08 | $130.53 | $105.86 |
| Total current liabilities | $1635.14 | $2459.94 | $2390.32 | $579.67 |
| Long term debt | $223.94 | $197.7 | $323.46 | $362.12 |
| Total noncurrent liabilities | $879.28 | $432.81 | $538.11 | $375.6 |
| Total debt | $229.08 | $549.78 | $453.99 | $467.98 |
| Total liabilities | $2514.42 | $2892.76 | $2928.43 | $955.27 |
| Shareholders' equity | ||||
| Retained earnings | -$4820.95 | -$4275.89 | -$3617.95 | -$1874.2 |
| Other shareholder equity | $2.72 | -$6.38 | -$1.35 | $7.02 |
| Total shareholder equity | -$716.93 | -$634.08 | -$351.67 | $627.21 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $84.51 | $415.48 | $93.86 | $291.34 |
| Cost of revenue | $46.24 | $59.21 | $154.98 | |
| Gross Profit | $23.89 | $369.24 | $34.65 | $136.37 |
| Operating activities | ||||
| Research & development | $106.95 | $92.68 | $164.7 | |
| Selling, general & administrative | $101.3 | $86.8 | $155.24 | |
| Total operating expenses | $153.71 | $208.24 | $179.48 | $319.93 |
| Operating income | $161 | -$144.83 | -$183.57 | |
| Income from continuing operations | ||||
| EBIT | $168.73 | -$141.18 | -$172.58 | |
| Income tax expense | -$1.03 | $2.21 | $2.26 | $1.69 |
| Interest expense | -$4.24 | $4.14 | $4.11 | $4.12 |
| Net income | ||||
| Net income | -$121.3 | $162.38 | -$147.55 | -$178.39 |
| Income (for common shares) | $162.38 | -$147.55 | -$178.39 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $983.71 | $1981.87 | $1146.29 | $475.6 |
| Cost of revenue | $343.77 | $902.64 | ||
| Gross Profit | $639.94 | $1079.23 | $1146.29 | $475.6 |
| Operating activities | ||||
| Research & development | $737.5 | $1235.28 | $2534.51 | $747.03 |
| Selling, general & administrative | $468.95 | $488.69 | $298.36 | $145.29 |
| Total operating expenses | $1206.45 | $1723.97 | $2832.87 | $892.32 |
| Operating income | -$566.51 | -$644.74 | -$1686.58 | -$416.72 |
| Income from continuing operations | ||||
| EBIT | -$528.62 | -$633.77 | -$1693.41 | -$403.11 |
| Income tax expense | $2.03 | $4.29 | $29.21 | |
| Interest expense | $14.42 | $19.88 | $21.13 | $15.14 |
| Net income | ||||
| Net income | -$545.06 | -$657.94 | -$1743.75 | -$418.26 |
| Income (for common shares) | -$545.06 | -$657.94 | -$1743.75 | -$418.26 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $162.38 | -$147.55 | -$178.39 | |
| Operating activities | ||||
| Depreciation | $11.13 | $12.15 | $10.79 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $14.1 | $11.56 | $15.66 | |
| Total cash flows from operations | $314.27 | -$83.56 | -$176.78 | |
| Investing activities | ||||
| Capital expenditures | -$3.13 | -$7.25 | -$9.08 | |
| Investments | -$369.58 | |||
| Total cash flows from investing | -$348.05 | -$372.71 | -$7.25 | -$9.08 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $258.58 | $6.25 | $102.71 | |
| Net borrowings | -$0.37 | -$0.36 | -$2.32 | |
| Total cash flows from financing | $264 | $258.22 | $5.89 | $100.39 |
| Effect of exchange rate | $2.92 | -$0.16 | -$2.96 | $2.92 |
| Change in cash and equivalents | $4.78 | $199.62 | -$87.87 | -$82.55 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$545.06 | -$657.94 | -$1743.75 | -$418.26 |
| Operating activities | ||||
| Depreciation | $41.23 | $29.05 | $157.09 | $250.75 |
| Business acquisitions & disposals | -$165.52 | |||
| Stock-based compensation | $85.36 | $130.3 | $183.63 | $128.03 |
| Total cash flows from operations | -$713.97 | -$415.94 | $322.95 | -$42.54 |
| Investing activities | ||||
| Capital expenditures | -$58.81 | -$92.98 | -$57.49 | -$54.62 |
| Investments | $157.64 | -$157.64 | ||
| Total cash flows from investing | -$58.81 | -$92.98 | $100.15 | -$377.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $360.4 | $248.59 | $589.62 | $920.09 |
| Net borrowings | -$352.35 | $81.66 | -$127.91 | -$96.06 |
| Total cash flows from financing | $4.47 | $324.99 | $461.71 | $984.76 |
| Effect of exchange rate | $3.27 | $4.52 | -$5.29 | $2.12 |
| Change in cash and equivalents | -$765.03 | -$179.41 | $879.52 | $566.56 |
News
Fundamentals
| Market cap | $1.36B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 160.15M |
| Revenue | $885.19M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$284.86M |
| Revenue Q/Q | -54.80% |
| Revenue Y/Y | -15.68% |
| P/E ratio | -4.79 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.54 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.78 |
|---|---|
| ROA | -17.05% |
| ROE | N/A |
| Debt/Equity | -3.51 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.93 |
| Quick ratio | 0.93 |